According to Reuters, the course of treatment with the new drug will consist of three tablets.

The American company Pfizer has signed an agreement with the Medicines Patent Pool (MPP), according to which its antiviral drug for the treatment of COVID-19, taken orally, can be delivered to 95 low- and middle-income countries of the world. This is stated in a press release posted on the company’s website on Tuesday.

“Qualified manufacturers of generic drugs (generics) all over the world, who have been granted sublicenses, will be able to supply PF-07321332/Ritonavir to 95 countries, which cover approximately 53% of the world’s population,” the statement says. The company emphasized its multilevel approach to pricing – low-income countries “will pay a non-commercial price” in contrast to high- and middle-income countries, for which the drug will cost more.

“We must work to ensure that all people – no matter where they live and in what conditions – have access to scientific breakthroughs, and we are pleased to work with MPP to strengthen our commitment to justice,” commented Pfizer CEO Albert Bourla.

Earlier, the company reported that the drug it produced according to the results of the second phase of the clinical trial showed an 89% reduction in the risk of hospitalization or death. Pfizer expressed a desire to obtain permission for the emergency use of its new drug by submitting data on the study to the U.S. Food and Drug Administration.

As noted by Reuters, the course of treatment with the new drug will consist of three tablets taken twice a day. According to the agency, Pfizer intends to produce more than 180 thousand doses of such a drug by the end of the year, and next year the number of doses is planned to increase to 50 million.

Earlier, Pfizer reported that the first phase of studies showed good tolerability and safety of the drug. According to their assessment, the new drug can potentially be taken when the first symptoms of coronavirus appear or after contact with an infected person without the need for hospitalization.